PTAB precedential decisions are the small subset of Board decisions that bind the Board.
Most decisions bind only the parties. A panel decides an inter partes review, the parties are bound, and the next panel is free to reason differently.
Designation is what changes that. It converts one panel's reasoning into a rule every panel follows.
And designations move. Decisions are added, superseded and de-designated, which makes checking the current list a different exercise from citing something you read about.
Three tiers
| Tier | Binds |
|---|---|
| Precedential | All Board panels |
| Informative | Nobody — guidance only |
| Routine | The parties only |
Informative decisions are frequently over-read. They illustrate how the Board approaches a recurring issue and provide no binding force, so a party relying on one as though it settles the point is overstating it.
Routine decisions are the vast majority, and citing one tells a panel what another panel did, nothing more.
How designation happens
| Route | Detail |
|---|---|
| Precedential Opinion Panel review | Panel convened to address a question of Board-wide importance |
| Designation by Board leadership | Through internal procedures |
| Director review | Post-Arthrex, the Director may review AIA decisions |
| Rulemaking | Can supersede decisions entirely |
This is administrative, not appellate. A decision does not become precedential by being appealed and affirmed; it becomes precedential by being designated.
Director review has reshaped this area since Arthrex, and decisions issued through it carry substantial weight in practice.
Why designation exists
| Problem | What designation solves |
|---|---|
| Panels reaching different results on the same issue | Consistency |
| Parties unable to predict outcomes | Predictability |
| Recurring procedural questions | Settles them once |
| No appellate route for practice questions | Administrative resolution |
The Board decides thousands of proceedings, and without designation the same question could be answered differently by different panels indefinitely.
Appeal does not solve this. Most procedural questions never reach the Federal Circuit, so the Board needs an internal mechanism to settle them.
What they most affect
| Area | Why it matters |
|---|---|
| Discretionary denial | Whether a petition is considered at all |
| Parallel district court litigation | Timing and duplication |
| Real party in interest and privity | Who is bound, and standing |
| Joinder | Adding parties or grounds |
| Motions to amend | Whether a patentee can narrow |
| Claim construction practice | How terms are read |
| Serial and parallel petitions | Multiple challenges to one patent |
Discretionary denial is where the movement has been. Whether the Board exercises discretion to decline institution can matter more to an outcome than any argument about the prior art, because a denied petition never reaches the merits.
A patent owner's best argument is frequently procedural. See PTAB discretionary denial.
Institution rates move with the framework
| Period | Approximate institution rate |
|---|---|
| October 2024 | ~65% |
| February 2026 | ~37% |
Always quote an institution figure with its date. The framework governing discretionary denial has changed substantially, and a rate cited without a date is close to meaningless.
This is a live area. Anyone planning a petition or a defence should check the current position rather than a figure from an article.
Precedential does not mean binding on courts
| Body | Bound by PTAB designations? |
|---|---|
| PTAB panels | Yes |
| District courts | No |
| Federal Circuit | No |
| USPTO examiners | Through separate guidance |
Federal Circuit decisions bind everyone, including the Board. The hierarchy runs one way.
Courts may find PTAB reasoning persuasive and are free to disagree, which is why a claim construction adopted at the Board does not settle the same question in parallel litigation.
Reading a designation
| Element | What to note |
|---|---|
| Current status | Precedential, informative, or neither |
| Date of designation | Not the same as the decision date |
| Scope | Which parts were designated — sometimes only a section |
| Later treatment | Distinguished, superseded, de-designated |
| Related rulemaking | Can override entirely |
Partial designation is common and easy to miss. Only a portion of a decision may be designated, so citing the whole thing as precedential overstates it.
Designation date differs from decision date, sometimes by years, which matters when assessing what governed a proceeding at a given time.
Checking a decision
| Step | Action |
|---|---|
| 1 | Find the decision on the USPTO PTAB pages |
| 2 | Check its current designation |
| 3 | Check whether later decisions address the same issue |
| 4 | Check whether rulemaking has superseded it |
| 5 | Check for Director review activity |
| 6 | Note the date of everything |
Step two is the one that gets skipped. A decision cited as precedential in a 2024 article may have been superseded, and nothing in the article will say so.
The USPTO's published list is the authoritative source, and it is free.
Worked example: two petitions, same art
Two petitioners challenge related patents with substantially the same references.
| Petition A | Petition B | |
|---|---|---|
| Filed | Early in the district court case | Shortly before trial |
| Parallel litigation | Scheduled far out | Trial date near |
| Prior art strength | Strong | Equally strong |
| Petitioner stipulation on overlapping grounds | Offered | Not offered |
| Discretionary denial argued | Yes | Yes |
| Outcome | Instituted | Denied |
The prior art was the same. The difference was procedural posture and timing.
Petition B never reached the merits. Its references were never evaluated, and the patent survived without being tested.
This is why discretionary denial precedent dominates practice. A petitioner who files late and offers nothing on duplication may lose before the substantive question is asked. See inter partes review.
Using them in a filing
| Practice | Why |
|---|---|
| Cite precedential decisions as binding | They are, on the Board |
| Cite informative decisions as guidance | Overstating invites correction |
| Verify designation before filing | Designations change |
| Address adverse precedent directly | A panel will find it anyway |
| Date every practice statistic | The landscape moves |
| Check Director review activity | It shapes the current position |
Address adverse precedent rather than omitting it. A panel bound by a decision you did not mention will notice, and the omission costs credibility on everything else.
Who this matters to
| Party | Why |
|---|---|
| Petitioners | Whether a petition will be instituted at all |
| Patent owners | Procedural defences before the merits |
| Litigation counsel | Timing petitions against trial dates |
| Patent buyers | Whether an asset has survived or faces challenge |
| Prosecutors | How claims are read at the Board |
Buyers care more than they realise. A patent under an instituted IPR is a different asset from one that survived a denial, and the reason for the denial matters.
Where this sits in a defence
| Stage | Question |
|---|---|
| 1 | Is the patent even in force? |
| 2 | Does the claim read on the product? |
| 3 | Does the prosecution history bar equivalents? |
| 4 | Is the patent invalid? |
| 5 | Would a petition be instituted? |
Stage one first, always. Only 41.4% of US utility patents reach full term — see the patent survival curve — and a lapsed patent needs no petition.
Stage five is a separate question from stage four. A strong invalidity case can be denied institution on discretionary grounds, which means the merits and the procedure have to be assessed independently.
PTAB precedential decisions: the checklist
- Most PTAB decisions bind only the parties. Designation is what changes that.
- Distinguish precedential from informative. Only the first binds panels.
- Designation is administrative, not the result of an appeal.
- Check the current designation before relying on any decision.
- Use the USPTO's published list, not a secondary summary.
- Watch Director review, which has reshaped this area since Arthrex.
- Quote institution rates with dates. They have moved from ~65% in October 2024 to ~37% in February 2026.
- Treat discretionary denial as a threshold question, separate from the merits.
- Remember courts are not bound by PTAB designations.
- Address adverse precedent directly in any filing.